EQUITY RESEARCH MEMO

Diazyme Laboratories

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)65/100

Diazyme Laboratories is a privately held diagnostic reagent company headquartered in San Diego, California. Founded in 1998, the company develops and manufactures high-quality enzyme and immunoassay reagents for automated clinical analyzers, serving healthcare professionals globally. Its proprietary technologies address critical needs in clinical chemistry, with a broad product portfolio that includes reagents for cardiac, diabetes, thyroid, and other disease markers. Diazyme's strong focus on innovation and quality has earned it a reputation as a reliable partner for hospitals and reference laboratories. Despite being private, the company has maintained steady growth by expanding its distribution network and investing in R&D.

Upcoming Catalysts (preview)

  • Q2 2026Launch of next-generation cardiac assay panel70% success
  • H2 2026Strategic distribution partnership in Asia-Pacific60% success
  • Q1 2027FDA clearance for expanded autoimmune test menu50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)